Country: Indonesia
Bahasa: Indonesia
Sumber: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency
SIMVASTATIN, EZETIMIBE
ORGANON PHARMA INDONESIA TBK - Indonesia
SIMVASTATIN, EZETIMIBE
10 MG /10 MG
TABLET
DUS, 3 BLISTER @ 10 TABLET
ORGANON PHARMA INDONESIA TBK - Indonesia
2021-07-17
VYTORIN TABLET Ezetimibe/Simvastatin COMPOSITION Each tablet of VYTORIN contains 10 mg of ezetimibe and 10 mg of simvastatin (VYTORIN 10/10), 20 mg of simvastatin (VYTORIN 10/20). Clinical testing has been conducted over the dose range 10 mg ezetimibe/10 mg simvastatin to 10 mg ezetimibe/80 mg simvastatin. THERAPEUTIC CLASS VYTORIN (ezetimibe/simvastatin) is a lipid-lowering product that selectively inhibits the intestinal absorption of cholesterol and related plant sterols and inhibits the endogenous synthesis of cholesterol. MECHANISM OF ACTIONS VYTORIN Plasma cholesterol is derived from intestinal absorption and endogenous synthesis. VYTORIN contains ezetimibe and simvastatin, two lipid-lowering compounds with complementary mechanisms of action. VYTORIN reduces elevated total-C, LDL-C, Apo B, TG, and non-HDL-C, and increases HDL-C through dual inhibition of cholesterol absorption and synthesis. EZETIMIBE Ezetimibe inhibits the intestinal absorption of cholesterol. Ezetimibe is orally active and has a mechanism of action that differs from other classes of cholesterol-reducing compounds (e.g., statins, bile acid sequestrants [resins], fibric acid derivatives, and plant stanols). The molecular target of ezetimibe is the sterol transporter, Niemann-PickC1- Like 1 (NPC1L1), which is responsible for the intestinal uptake of cholesterol and phytosterols. DISETUJUI OLEH BPOM : 24/03/2022 ID : EREG100373VR12200068 EREG100373VR12200069 Ezetimibe localizes at the brush border of the small intestine and inhibits the absorption of cholesterol, leading to a decrease in the delivery of intestinal cholesterol to the liver; statins reduce cholesterol synthesis in the liver and together these distinct mechanisms provide complementary cholesterol reduction. In a 2-week clinical study in 18 hypercholesterolemic patients, Ezetimibe inhibited intestinal cholesterol absorption by 54%, compared with placebo. A series of preclinical studies was performed to determine the selectivity of ezetimibe for inhibiting cholesterol absorpti Baca dokumen lengkap